Mellalta Meets | Business Consulting
We provide custom-built intelligence decks for each client so they can see exactly where they stand in relation to their competitors—and what it takes to get there. Mellalta Meets has a team of seasoned executives who are experts in competitive intelligence, strategic planning, market research and client management. We also offer syndicated reports that highlight key areas of focus for our clients’ industry verticals, so they can make strategic decisions based on real data instead of guesswork. Disease Report Store provides latest reports, strategies and Key Leader opinions in this market. This is the opportunity to develop your ideas and thinking while having your efforts recognized from day one.
This company is:
Verified
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032 - Mellalta Meets
The Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032. The Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.
Verified
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032 - Mellalta Meets
Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032 Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
Verified
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032 - Mellalta Meets
The ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032. The ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032.
View all products
Keywords
Industries
Where is Mellalta Meets located?
The company Mellalta Meets is located in London, England, United Kingdom. It's worth noting that the company may has more corporate locations
How many employees does Mellalta Meets approximately have?
As of the latest available information Mellalta Meets has around 11-50 employees worldwide.
In which industries does Mellalta Meets mainly work?
The company Mellalta Meets has it's main focus in the industries of Data and Analytics
FedSavvy Strategies
United States
1-10 Employees
2012
Market Intelligence Data
United States
51-100 Employees
2016
Agrochemical Industry News
United States
11-50 Employees
Market Insights Reports (Ameliorate Digital Consultancy Pvt Ltd. Group Company)
United States
51-100 Employees
2016
Meridian Market Consultants
51-100 Employees
2017
Midesk
Germany
1-10 Employees
2019
Market intelliX
India
11-50 Employees
Value Market Research
India
11-50 Employees
2015
Topics which have been searched by others and may be interesting for you: